Navigation Links
Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
Date:10/26/2010

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at Oppenheimer's 21st Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, November 2, 2010, at 10:15 a.m. Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcast of this presentation will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of this presentation will be available at the same location for 30 days after the presentation.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA to the EMA (Europe) for fidaxomicin.  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. We plan to have an NDA submitted to the FDA in the first quarter of 2011.
Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer &
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
2. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
3. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
4. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
9. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
10. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
11. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.024 11/2001 , ... , , , , , ... line), , , ...
... , , , , , , Multiporator / Electroporator 2510 , , , ... , Transformation Protocol , Protocol No. 4308 915.512 ... , , , , , , ... , Cell type , ...
... , , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.022 11/1999 , ... , , , Cell line , ... Transfection with , Plasmid RSV/lacZ (in bidistilled H 2 O), ...
Cached Biology Technology:H73C11 2H73C11 3Escherichia coli DH5 2Escherichia coli DH5 3COS-7 2
(Date:8/20/2014)... A new gene therapy developed by researchers at ... shown to protect mice from a life-threatening heart condition ... new therapeutic avenue," said Yi Lai, Ph.D., the leading ... the MU School of Medicine,s Department of Molecular Microbiology ... we hope this could lead to a treatment for ...
(Date:8/20/2014)... researchers have developed methods for electronically manipulating the flight ... moths use to control those muscles. The work opens ... "biobots," for use in emergency response. , "In the ... control the movement of moths for use in applications ... Bozkurt, an assistant professor of electrical and computer engineering ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Research paves way for development of cyborg moth 'biobots' 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Researchers at the University of Illinois at Chicago College ... on the nervous system to create the devastation of Huntington,s ... Nature Neuroscience online. The researchers were able to ... called JNK3, which is expressed only in neurons and, further, ...
... soil microbe that uses chemical warfare to fight off ... of its arsenal, researchers report, making use of an ... known to do: break a non-activated carbon-carbon bond in ... in the journal Nature , provides the first ...
... play a role in growth of some types of ... cancer development, say researchers from the Lombardi Comprehensive Cancer ... findings, presented at the annual meeting of the Endocrine ... this protein, known as Stat5a, may be different in ...
Cached Biology News:Huntington's disease deciphered 2Huntington's disease deciphered 3Researchers describe 'implausible' chemistry that produces herbicidal compound 2Dual role in breast tissue for a protein involved in leukemia 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... Source produces a powerful, stable output from 215-400 ... source are available, providing a wavelength range of ...
... and mitochondrial membrane potential. The mitochondrial permeability ... the initiation of cellular apoptosis. This process ... the electrochemical gradient across the mitochondrial membrane, ... membrane potential (YD). Loss of mitochondrial YD ...
Biology Products: